# Neurolightech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neurolightech

- Industry: Medical Devices & Equipment
- Headquarters: Tokyo, Japan
- Website: www.nlt-md.com/
- Total disclosed funding: $1.3M
- Latest round: Series A (Jul 1, 2021)
- Investors on record: 1

## About

Based in Japan, Neurolightech Inc. specializes in the development of innovative medical devices that utilize light technology for therapeutic applications, particularly targeting malignant tumors and cardiac conditions.Neurolightech Inc. was founded in 2018 and is headquartered in Tokyo, Japan. The company develops innovative medical devices employing light technology for medical treatments. In July 2021, Neurolightech raised JPY 140 million in a Series A funding round led by RMD Partners, who acquired 47% of shares. The total amount raised by the company is JPY 140 million, with a current valuation of JPY 354.118 million.Neurolightech Inc. specializes in the development and sales of innovative medical devices that utilize light technology for therapeutic applications. The company's core offerings include treatments for malignant tumors, such as cervical cancer, and cardiac arrhythmias, leveraging unique light wavelengths identified for their efficacy in medical treatments. Their flagship technology, known as light ablation, employs common visible light spectra, making it potentially less invasive and more patient-friendly. Neurolightech’s products aim to address significant medical needs, particularly in Japan and potentially other Asian markets, by providing advanced therapeutic solutions that reduce pain while ensuring effective treatment outcomes. The target customer base includes healthcare providers, hospitals, and clinics seeking medical devices to enhance patient care.Neurolightech's revenue model is primarily structured around direct sales of its medical devices to healthcare facilities and practitioners. Transactions typically occur on a B2B basis, where clients purchase devices tailored to specific treatment needs. The company may also engage in partnerships with medical institutions or distributors to enhance its market reach. Pricing structures for the products are established based on the technological advancements and therapeutic benefits they offer, aligning with industry standards for medical devices. Revenue generated supports continued innovation and development in the company’s product line, fostering growth in the emerging field of light-based medical treatments.In July 2021, Neurolightech raised JPY 140 million in Series A funding from RMD Partners, who will provide hands-on management support, leveraging their knowledge and network for growth and development. This funding will be utilized to support the launch of new products designed to improve therapeutic applications using light technology. Neurolightech aims to expand its market presence by targeting additional Asian markets, enhancing access to its innovative medical devices by the end of 2023.

## Funding rounds

- Series A, Jul 1, 2021, $1.3M — RMD Partners

## Investors

- RMD Partners (https://capitalatlas.ai/funds/rmd-partners) — Series A